+关注
层层加码
暂无个人介绍
IP属地:上海
15
关注
0
粉丝
0
主题
0
勋章
主贴
热门
层层加码
2021-12-21
$知乎(ZH)$
最喜欢看zhihu了l
层层加码
2021-12-06
非常好的药物
@天境生物:天境生物宣布CD73抗体尤莱利单抗(Uliledimab)与阿替利珠单抗联用 治疗晚期实体瘤的2期临床研究完成首例两名患者给药
层层加码
2021-12-06
抓紧
花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元
层层加码
2020-03-11
$Lyft, Inc.(LYFT)$
还有底线吗?!
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3540115495846811,"uuid":"3540115495846811","gmtCreate":1577021509530,"gmtModify":1674184367098,"name":"层层加码","pinyin":"ccjmcengcengjiama","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":15,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"上海","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691054436,"gmtCreate":1640101524206,"gmtModify":1640101524206,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZH\">$知乎(ZH)$</a>最喜欢看zhihu了l","listText":"<a href=\"https://laohu8.com/S/ZH\">$知乎(ZH)$</a>最喜欢看zhihu了l","text":"$知乎(ZH)$最喜欢看zhihu了l","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691054436","isVote":1,"tweetType":1,"viewCount":973,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606072348,"gmtCreate":1638803965985,"gmtModify":1638803965985,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"非常好的药物","listText":"非常好的药物","text":"非常好的药物","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606072348","repostId":"601223271","repostType":1,"repost":{"id":601223271,"gmtCreate":1638537202986,"gmtModify":1638537202986,"author":{"id":"3546318476404641","authorId":"3546318476404641","name":"天境生物","avatar":"https://static.tigerbbs.com/6c790321aa0e34c85e2c789416a37e11","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"天境生物宣布CD73抗体尤莱利单抗(Uliledimab)与阿替利珠单抗联用 治疗晚期实体瘤的2期临床研究完成首例两名患者给药","htmlText":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","listText":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","text":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601223271","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606081583,"gmtCreate":1638801528458,"gmtModify":1638801528458,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"抓紧","listText":"抓紧","text":"抓紧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606081583","repostId":"2189506193","repostType":2,"repost":{"id":"2189506193","pubTimestamp":1638780360,"share":"https://www.laohu8.com/m/news/2189506193?lang=&edition=full","pubTime":"2021-12-06 16:46","market":"us","language":"zh","title":"花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2189506193","media":"美港电讯","summary":"花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.ZLAB&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1\" width=\"578\"/></p><p> <a href=\"https://laohu8.com/S/C\">花旗</a>:将<span><a href=\"https://laohu8.com/S/ZLAB\">再鼎医药</a></span><span></span>(ZLAB.O)目标价从217美元上调至231美元。 </p><p>(文章来源:美港电讯)</p>\n</div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 16:46 北京时间 <a href=http://stock.eastmoney.com/a/202112062204275745.html><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元。 (文章来源:美港电讯)</p>\n\n<a href=\"http://stock.eastmoney.com/a/202112062204275745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","relate_stocks":{"ZLAB":"再鼎医药","09688":"再鼎医药"},"source_url":"http://stock.eastmoney.com/a/202112062204275745.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189506193","content_text":"花旗:将再鼎医药(ZLAB.O)目标价从217美元上调至231美元。 (文章来源:美港电讯)","news_type":1},"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965150223,"gmtCreate":1583937171962,"gmtModify":1704351659923,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LYFT\">$Lyft, Inc.(LYFT)$</a>还有底线吗?!","listText":"<a href=\"https://laohu8.com/S/LYFT\">$Lyft, Inc.(LYFT)$</a>还有底线吗?!","text":"$Lyft, Inc.(LYFT)$还有底线吗?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/965150223","isVote":1,"tweetType":1,"viewCount":3427,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":965150223,"gmtCreate":1583937171962,"gmtModify":1704351659923,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LYFT\">$Lyft, Inc.(LYFT)$</a>还有底线吗?!","listText":"<a href=\"https://laohu8.com/S/LYFT\">$Lyft, Inc.(LYFT)$</a>还有底线吗?!","text":"$Lyft, Inc.(LYFT)$还有底线吗?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/965150223","isVote":1,"tweetType":1,"viewCount":3427,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691054436,"gmtCreate":1640101524206,"gmtModify":1640101524206,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZH\">$知乎(ZH)$</a>最喜欢看zhihu了l","listText":"<a href=\"https://laohu8.com/S/ZH\">$知乎(ZH)$</a>最喜欢看zhihu了l","text":"$知乎(ZH)$最喜欢看zhihu了l","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691054436","isVote":1,"tweetType":1,"viewCount":973,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606072348,"gmtCreate":1638803965985,"gmtModify":1638803965985,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"非常好的药物","listText":"非常好的药物","text":"非常好的药物","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606072348","repostId":"601223271","repostType":1,"repost":{"id":601223271,"gmtCreate":1638537202986,"gmtModify":1638537202986,"author":{"id":"3546318476404641","authorId":"3546318476404641","name":"天境生物","avatar":"https://static.tigerbbs.com/6c790321aa0e34c85e2c789416a37e11","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"天境生物宣布CD73抗体尤莱利单抗(Uliledimab)与阿替利珠单抗联用 治疗晚期实体瘤的2期临床研究完成首例两名患者给药","htmlText":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","listText":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","text":"中国上海和美国盖瑟斯堡 - 2021年12月3日 –天境生物(“公司”)(纳斯达克股票代码:IMAB)是一家从临床阶段正迈向商业化的生物药公司,致力于创新生物药的靶点生物学研究、抗体工艺及中美临床开发和产品商业化,为全球范围内需求迫切的癌症治疗领域,提供新型有效的治疗手段。公司今天宣布,其自主研发的CD73抗体尤莱利单抗(uliledlimab,也称为TJD5)与阿替利珠单抗(泰圣奇®)联用治疗卵巢癌及其它特定晚期或转移性实体瘤的美国2期剂量扩展研究(NCT05001347)已完成首例两名患者给药。CD73是一种表达于肿瘤细胞、催化单磷酸腺苷(AMP)向腺苷转化的限速酶,而腺苷在肿瘤微环境中有免疫抑制作用。尤莱利单抗作为一款创新型CD73人源化抗体,可通过识别独特的抗原表位完全抑制CD73的活性,降低腺苷生成从而解除其介导的免疫抑制,激发抗肿瘤活性。另外,尤莱利单抗以“内二聚体”的结合模式完全抑制CD73的活性,这一差异化优势有望解决其它CD73抗体中常见的量效背离的“钩状效应”难题以提高成药性。尤莱利单抗和阿替利珠单抗联用治疗晚期癌症患者的1期临床数据显示了良好的安全性、耐受性和初步疗效信号。该美国2期临床试验是一项多中心、开放标签的剂量扩展研究,旨在评估尤莱利单抗与阿替利珠单抗联用治疗特定晚期或转移性实体瘤患者的临床疗效及潜在生物标记物。研究将由两个扩展队列组成,包括对铂类治疗耐药的卵巢癌患者的剂量扩展队列,以及针对生物标志物驱动的“篮式”研究队列(包括PD-L1表达≥1%的头颈部鳞状细胞癌、非小细胞肺癌、胃肠道癌、三阴乳腺癌或卵巢癌患者)。该试验与目前正在中国开展的尤莱利单抗的临床研究一起,针对不同实体瘤进行临床研究,以加速公司推进尤莱利单抗进入关键临床研究阶段。天境生物首席执行官申华琼博士表示:“尤莱利单抗的独特作用机理及1期临床数据充分展示其拥有治疗多种癌症、尤其","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601223271","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606081583,"gmtCreate":1638801528458,"gmtModify":1638801528458,"author":{"id":"3540115495846811","authorId":"3540115495846811","name":"层层加码","avatar":"https://static.tigerbbs.com/9f348c538031287bc542ab9be48c84ea","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"抓紧","listText":"抓紧","text":"抓紧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606081583","repostId":"2189506193","repostType":2,"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}